Silymarin downregulates COX-2 expression and attenuates hyperlipidemia during NDEA-induced rat hepatocellular carcinoma.

Authors: Ramakrishnan, G  Elinos-Baez, CM  Jagan, S  Augustine, TA  Kamaraj, S  Anandakumar, P  Devaki, T 
Citation: Ramakrishnan G, etal., Mol Cell Biochem. 2008 Jun;313(1-2):53-61. Epub 2008 Mar 31.
Pubmed: (View Article at PubMed) PMID:18373278
DOI: Full-text: DOI:10.1007/s11010-008-9741-5

Silymarin is a naturally available bioflavonoid and is a strong antioxidant with a capacity to inhibit the formation of tumors in several cancer models. In the present study, we investigated whether dietary supplementation of silymarin has any role in lipid components, lipid-metabolizing enzymes, free fatty acid profile, and expression of cyclooxygenase-2 (COX-2) in N-nitrosodiethylamine (NDEA)-induced hepatocellular carcinoma in rats. NDEA-induced rats showed severe hyperlipidemia along with upregulated expression of COX-2 as revealed by western blotting and immunohistochemistry. Dietary silymarin supplementation attenuated this hyperlipidemia and downregulated the expression of COX-2. Thus we conclude that compounds like silymarin with potent hypolipidemic effect are strong candidates as chemopreventive agents for the treatment of liver cancer.


Disease Annotations
Gene Ontology Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 2300283
Created: 2008-09-10
Species: All species
Last Modified: 2008-09-10
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.